Brief: Agenus Completes Enrollment In Randomized Phase 2 Clinical Trial Of Botensilimab/Balstilimab In Advanced Colorectal Cancer
10/10/2023 12:37
Oct 10 (Reuters) - Agenus Inc AGEN.O :
* AGENUS COMPLETES ENROLLMENT IN RANDOMIZED PHASE 2 CLINICAL
TRIAL
OF BOTENSILIMAB/BALSTILIMAB IN ADVANCED COLORECTAL CANCER
* AGENUS COMPLETES ENROLLMENT IN RANDOMIZED PHASE 2 CLINICAL
TRIAL
OF BOTENSILIMAB/BALSTILIMAB IN ADVANCED COLORECTAL CANCER
* AGENUS INC - IS EXPLORING GLOBAL ACCELERATED APPROVAL
STRATEGIES
FOR CRC
Source text for Eikon: ID:nBw6C7WJNa
Further company coverage: AGEN.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Agenus
See all newsBrief: Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026
Brief: Armenia Grants First Marketing Authorizations For Agenus’ Bot+Bal In Previously Treated Mss Metastatic Colorectal Cancer
Brief: Agenus - Unit Enters Second Loan Modification Agreement With Ocean 1181 On Aug 12, 2026 - SEC Filing
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Q2 revenue rises on access and royalty income